Clinical trials: Cystitis
Interstitial Cystitis
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
To evaluate the safety and efficacy of 8 weeks of treatment with MN-001 at 500 mg bid, 500 mg once daily vs. placebo in patients with Interstitial Cystitis.
- Trial name
- NCT00295854
- Testing
- MN-001 BID, MN-001
- Where
- 28 sites in United States
- Volunteers
- 296 people
- Sponsor
- MediciNova